Jeffrey A Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1798345/publications.pdf

Version: 2024-02-01

471509 501196 1,037 30 17 28 citations h-index g-index papers 32 32 32 693 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	CIDP diagnostic pitfalls and perception of treatment benefit. Neurology, 2015, 85, 498-504.	1.1	188
2	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€"Second revision. Journal of the Peripheral Nervous System, 2021, 26, 242-268.	3.1	176
3	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. European Journal of Neurology, 2021, 28, 3556-3583.	3.3	153
4	Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle and Nerve, 2018, 57, 542-549.	2.2	56
5	Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: A retrospective study of complications and outcome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 308-314.	1.7	49
6	Ocular myasthenia gravis in a senior population: Diagnosis, therapy, and prognosis. Muscle and Nerve, 2010, 41, 379-384.	2.2	41
7	Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle and Nerve, 2019, 60, 180-183.	2.2	37
8	Optimizing IgG therapy in chronic autoimmune neuropathies: A hypothesis driven approach. Muscle and Nerve, 2015, 51, 315-326.	2.2	33
9	Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review. Patient Preference and Adherence, 2021, Volume 15, 811-834.	1.8	32
10	Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. Brain and Behavior, 2018, 8, e00932.	2.2	26
11	Risk factors for the development of paclitaxelâ€induced neuropathy in breast cancer patients. Journal of the Peripheral Nervous System, 2018, 23, 129-133.	3.1	26
12	Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care. JAMA Neurology, 2020, 77, 1159.	9.0	26
13	The Misdiagnosis of CIDP: A Review. Neurology and Therapy, 2020, 9, 43-54.	3.2	25
14	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
15	Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2021, 28, 2065-2073.	3. 3	23
16	Individualized immunoglobulin therapy in chronic immuneâ€mediated peripheral neuropathies*. Journal of the Peripheral Nervous System, 2018, 23, 78-87.	3.1	21
17	Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?. Journal of the Neurological Sciences, 2020, 408, 116497.	0.6	21
18	Quantifying Treatment-Related Fluctuations in CIDP. Neurology, 2021, 96, e1876-e1886.	1.1	15

#	Article	IF	CITATIONS
19	Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2020, 62, 673-680.	2.2	12
20	Reversible demyelinating neuropathy associated with renal cell carcinoma. Neuromuscular Disorders, 2011, 21, 227-231.	0.6	8
21	Chronic Demyelinating Polyneuropathies. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1310-1331.	0.8	8
22	Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy. US Neurology, 2017, 13, 26.	0.2	8
23	A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. Advances in Therapy, 2021, 38, 316-328.	2.9	6
24	Measuring treatment response to chronic inflammatory demyelinating polyneuropathy in clinical practice: More than just asking. Muscle and Nerve, 2021, 64, 1-3.	2.2	6
25	Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Review of Neurotherapeutics, 2021, 21, 805-816.	2.8	6
26	Acquired Immunologic Neuropathies. Seminars in Neurology, 2015, 35, 398-406.	1.4	5
27	Total spinal and brainstem anesthesia as complication of paravertebral ropivacaine administration. Neurology: Clinical Practice, 2017, 7, 430-432.	1.6	4
28	Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. Neurodegenerative Disease Management, 2016, 6, 237-247.	2.2	2
29	Reply. Muscle and Nerve, 2018, 57, E132-E133.	2.2	0
30	Could posturography be a useful outcome measure for chronic inflammatory demyelinating polyneuropathy?. Muscle and Nerve, 2022, 65, 7-9.	2.2	0